MetaCap

Cullinan Therapeutics (CGEM) vs DBV Technologies S.A. (DBVT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cullinan Therapeutics (CGEM) has outperformed DBV Technologies S.A. (DBVT) over the past year, losing 6.1% versus a loss of 34.4%. Over five years, DBVT leads with a +50.3% price change compared with -51.2% for CGEM. Cullinan Therapeutics is the larger company by market cap ($577.1 million vs $566.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CGEM-6.12%DBVT-34.40%
+151%+53%-44%
Nov 21, 20251 yearNov 20, 2026
CGEM-54.34%DBVT+47.43%
+321%+104%-112%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CGEM versus DBVT key metrics
MetricCGEMDBVT
Share price$8.89$9.02
Market cap$577.15M$566.82M
1-day change-1.98%-4.25%
YTD return-14.11%-52.95%
1-year return-6.12%-34.40%
5-year return-51.21%+50.33%
EPS (TTM)$-3.09$-3.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$5.64M
Revenue growth (YoY)—+35.77%
Net income (latest FY)$-219.88M$-146.95M
Operating margin—-2609.23%
Net margin—-2607.29%
52-week high$23.19$26.19
52-week low$8.47$8.63
Distance from 52-week high-61.66%-65.55%
Analyst consensusstrong_buybuy
Avg. price target upside+285.49%+305.10%
Average volume997.14K352.88K
Shares outstanding64.92M62.84M
Employees109179
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CGEM has outperformed DBVT by 28.3 percentage points over the past year.

About Cullinan Therapeutics

CGEM stock →

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees

About DBV Technologies S.A.

DBVT stock →

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 179 employees

CGEM vs DBVT FAQ

Which is bigger, Cullinan Therapeutics or DBV Technologies S.A.?

Cullinan Therapeutics (CGEM) is larger, with a market capitalization of $577.15M compared with $566.82M for DBV Technologies S.A. (DBVT).

Which stock has performed better over the past year, CGEM or DBVT?

CGEM returned -6.12% over the past 12 months, compared with -34.40% for DBVT (price return, excluding dividends). Past performance does not predict future results.

Are Cullinan Therapeutics and DBV Technologies S.A. in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons